Document is current

Article History

Received: 3 May 2025

Accepted: 29 July 2025

First Online: 25 August 2025

Declarations

:

: Ethics approval for the IMPEDE-PKD trial was obtained in Queensland, Australia, from Metro South Hospital and Health Service Human Research and Ethics Committee (approval reference HREC/2021/QMS/70436). The study has received local governance approvals at each of the participating sites. Each participating jurisdiction will ensure relevant regulatory and ethical approvals are received prior to the trial beginning in that country.

: Consent for publication is not applicable since there are no identifying images or other personal or clinical details of participants presented. A model participant information sheet and consent form are provided.

: AJM has previously received research funding from Sanofi-Genzyme, been a member of a Medical Advisory Board for Otsuka Australia, and been clinical trial local site Principal Investigator for Reata, Sanofi-Genzyme and Dicerna. AJM is supported by a Queensland Government Advancing Clinical Research Fellowship. DWJ has received consultancy fees, research grants, speaker’s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca, Bayer and AWAK, speaker’s honoraria from ONO and Boehringer Ingelheim & Lilly, and travel sponsorships from Ono and Amgen. VJ reports consulting fee/honoraria from Bayer, Astra Zeneca, Boehringer Ingelheim, Biocryst, Vera, Visterra, Otsuka, Novartis, Astra Zeneca, Chinook, Biocryst and Alpine under the policy of all payments going to the organization. The other coauthors declare no relevant conflicts of interest.